CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Atossa Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Atossa Therapeutics Inc
107 Spring St
Phone: (206) 588-0256p:206 588-0256 SEATTLE, WA  98104-1005  United States Ticker: ATOSATOS
Business Summary
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing medicines in areas of unmet medical need in oncology with a focus on breast cancer. The Company’s lead drug candidate under development is oral (Z)-endoxifen, which the Company is developing in two settings: one to treat breast cancer by reducing tumor cell activity prior to surgery and another to reduce breast tissue density in women. Its programs under development include (Z)-endoxifen Programs, AT-H201, and other programs. (Z)-endoxifen is an active metabolite of tamoxifen, to treat and prevent breast cancer in high-risk women. It is developing a form of (Z)-endoxifen, which is administered orally for the potential treatment of breast cancer and reduction of breast density. AT-H201 is for lung injury caused by cancer treatments. AT-H201 consists of a combination of two drugs to treat other diseases. Its other programs include Immunotherapy/CAR-T Programs, which is in early stage of development.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023YesYes---

Industries
SIC Code Description
3841 Surgical and medical instruments and apparatus
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, President, Chief Executive Officer Steven C.Quay 72 4/1/2009 4/1/2009
Principal Financial and Accounting Officer HeatherRees 51 10/5/2023 10/5/2023
Director Shu-ChihChen 61 8/15/2014 4/1/2009
4 additional Officers and Directors records available in full report.

Business Names
Business Name
123Atossa Genetics, Inc.
ATOS
Atossa Genetics AUS Pty Ltd.
Atossa Genetics UK Ltd.
Atossa Genetics, Inc.

General Information
Number of Employees: 10 (As of 12/31/2023)
Outstanding Shares: 125,304,064 (As of 12/31/2023)
Shareholders: 41
Stock Exchange: NASD
Federal Tax Id: 264753208
Fax Number: (302) 636-5454


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, April 24, 2024